Last updated on February 2018

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy


Brief description of study

Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy.

Detailed Study Description

XELOX

  • Xeloda, 1000mg/ bid, day 1-15, every 3 weeks
  • Oxaliplatin 130mg/, day 1, every 3 weeks Until disease progression, patient's refusal or up to 8 cycles (maximum).

Clinical Study Identifier: NCT02350686

Contact Investigators or Research Sites near you

Start Over

sungju park

Samsung Medical Center
Seoul, Korea, Republic of
  Connect »